Till startsida
Sahlgrenska Academy Institute of Neuroscience and Physiology
Sitemap
To content Read more about how we use cookies on gu.se

Contact form




 


Note! If you want an answer on a question you must specify your email address


Jan Lycke

Professor, adjungerad

OverviewPublicationsUNDEFINEDUNDEFINEDUNDEFINED

Jan Lycke
Professor, adjungerad
jan.lycke@gu.se
+46 31-342 9047
0733-109149

Postal Address: Gröna stråket 11, plan 3, 41345 Göteborg
Visiting Address: Neurosjukvården, Gröna stråket 11, plan 3, SU/Sahlgrenska sjukhuset , 41345 Göteborg


Department of Clinical Neuroscience at Institute of Neuroscience and Physiology (More Information)
Box 430
405 30 Göteborg
Visiting Address: Blå stråket 7, plan 3, Sahlgrenska , 413 45 Göteborg

Research areas

Latest publications

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Bénédicte Delcoigne, Ali Manouchehrinia, Christian Barro, Pascal Benkert, Zuzanna Michalak et al.
Neurology, Journal article 2020
Journal article

Read the full text
on a web page

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn et al.
Annals of Neurology, Journal article 2020
Journal article

Read the full text
on a web page

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
Anna He, Bernd Merkel, James William L Brown, Lana Zhovits Ryerson, Ilya Kister et al.
The Lancet. Neurology, Journal article 2020
Journal article

Read the full text
on a web page

Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
G. Luna, P. Alping, J. Burman, K. Fink, A. Fogdell-Hahn et al.
JAMA Neurology, Journal article 2020
Journal article

Read the full text
on a web page

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS
Mathias Granqvist, Joachim Burman, Martin Gunnarsson, Jan Lycke, Petra Nilsson et al.
Multiple Sclerosis Journal, Journal article 2019
Journal article

Read the full text
on a web page

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.
Åsa P Sandelius, Sofia Sandgren, Markus Axelsson, Clas Malmeström, Lenka Novakova et al.
Scientific reports, Journal article 2019
Journal article

Read the full text
on a web page

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
Claire Bridel, Wessel N van Wieringen, Henrik Zetterberg, Betty M Tijms, Charlotte E Teunissen et al.
JAMA neurology, Journal article 2019
Journal article

Read the full text
on a web page

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
G. Comi, R. Alroughani, A. L. Boster, A. D. Bass, R. Berkovich et al.
Multiple Sclerosis Journal, Journal article 2019
Journal article

Read the full text
on a web page

An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational study.
Johan Lindström, Anders Helldén, Jan Lycke, Anna Grahn, Marie Studahl
The Journal of antimicrobial chemotherapy, Journal article 2019
Journal article

Read the full text
on a web page

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
B. Van Wijmeersch, B. A. Singer, A. Boster, S. Broadley, O. Fernandez et al.
Multiple Sclerosis Journal, Journal article 2019
Journal article

Read the full text
on a web page

Showing 61 - 70 of 77

2011

reply to Letter to the Editor "The neurofilament light chain is not stable in vitro"
M Gunnarsson, Clas Malmeström, Lars Rosengren, Jan Lycke, A Svenningsson
Annals of Neurol, Magazine article 2011
Magazine article

Read the full text
on a web page

Allmän neurologi och multipel skleros
Jan Lycke, Mats Elm
Neurologi. Läkemedelsboken 2011–2012 , Läkemedelsverket, Chapter in book 2011
Chapter in book

High nationwide prevalence of multiple sclerosis in Sweden.
Cecilia Ahlgren, Anders Odén, Jan Lycke
Multiple sclerosis (Houndmills, Basingstoke, England), Journal article 2011
Journal article

Read the full text
on a web page

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Per Soelberg Sorensen, Jan Lycke, Juha-Pekka Erälinna, Astrid Edland, Xingchen Wu et al.
Lancet neurology, Journal article 2011
Journal article

Read the full text
on a web page

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Carolina Holmén, Fredrik Piehl, Jan Hillert, Anna Fogdell-Hahn, Malin Lundkvist et al.
Multiple sclerosis (Houndmills, Basingstoke, England), Journal article 2011
Journal article

Read the full text
on a web page

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.
Martin Gunnarsson, Clas Malmeström, Markus Axelsson, Peter Sundström, Charlotte Dahle et al.
Annals of neurology, Journal article 2011
Journal article

Read the full text
on a web page

2010

Leukocyte myeloperoxidase and pathogenesis of the post-polio syndrome
Charlotta Movitz, Tomas Bergström, Kristian Borg, Kristoffer Hellstrand, Erik Lycke et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, Journal article 2010
Journal article

Read the full text
on a web page

Successful epilepsy surgery in a patient with neurosarcoidosis
Kristina Malmgren, Jan Lycke, Elisabeth Engman, Anders Hedström, Lars Jönsson et al.
Epilepsia, Journal article 2010
Journal article

Read the full text
on a web page

High risk of MS in Iranian immigrants in Gothenburg, Sweden.
Cecilia Ahlgren, Jan Lycke, Anders Odén, Oluf Andersen
Multiple sclerosis journal, Journal article 2010
Journal article

Read the full text
on a web page

[Neuromyelitis optica--important differential diagnosis to MS. Early treatment initiation crucial for the prognosis].
Jan Lycke, Clas Malmeström
Läkartidningen, Review article 2010
Review article

Read the full text
on a web page

Showing 61 - 70 of 77

Page Manager: Katinka Almrén|Last update: 9/1/2015
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://neurophys.gu.se/english/departments/clinical_neuroscience_and_rehabilitation/about-us/staff/?publicationPageNumber=7&selectedTab=2&feedbackForm=true&returnAddress=http%3A%2F%2Fneurophys.gu.se%2Fenglish%2Fdepartments%2Fclinical_neuroscience_and_rehabilitation%2Fabout-us%2Fstaff%2F%3Fprint%3Dtrue%26languageId%3D100001%26userId%3Dxlycja&recipientName=Katinka+Almr%E9n&encodedEmail=a2F0aW5rYS5hbG1yZW5AbmV1cm8uZ3Uuc2U&languageId=100001&userId=xlycja
Utskriftsdatum: 2020-07-09